The Safety and Efficacy of Good Feeling Power® for IBD Patients

NCT07766733 | Completed

• 1 other identifier: GFP_IDA14-1
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.

Conditions

Ulcerative Colitis (UC); Crohn Disease (CD)

Outcome Measures

Primary Outcomes (1)

• The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters

  The primary outcomes are the changes in gastrointestinal symptoms (Simple Clinical Colitis Activity Index for ulcerative colitis (UC) patients and the Harvey-Bradshaw Index for Crohn's disease (CD) patients), biochemical biomarkers in feces (calprotectin, immunoglobulin A, hemoglobin), and endoscopic parameters (Mayo Endoscopic Score).

  From baseline to Day180

Secondary Outcomes (1)

• Safety of Good Feeling Power® for patients with mild-to-moderate UC or CD

  From baseline to Day180

Study Arms (1)

The dietary supplement Good Feeling Power® was administered to all enrolled patients.

EXPERIMENTAL

Dietary Supplement: Good Feeling Power®

Interventions

Good Feeling Power® DIETARY_SUPPLEMENT

The dietary supplement Good Feeling Power®, isolated from the fruiting bodies of the tree mushroom (tinder fungus, lat. Fomes fomentarius), was administered orally as a drink.

The dietary supplement Good Feeling Power® was administered to all enrolled patients.

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adults aged 18 - 64
• BMI 18.5 - 32.0 kg/m²
• Mild-to-moderate UC or colonic/ileal CD
• At least one prior episode of active disease

You may not qualify if:

• Extensive colonic resection or subtotal or total colectomy
• Currently required or anticipated surgical intervention during the study
• Any prior exposure to natalizumab, efalizumab, or rituximab
• History or evidence of colonic mucosal dysplasia
• Female patients who are lactating or have a positive pregnancy test
• Any unstable or uncontrolled medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety.

Sponsors & Collaborators

• Good Feeling Products GmbH: lead

Study Sites (1)

Centro Medico Teknon

Barcelona, 08022, Spain

Location

MeSH Terms

Conditions

Colitis, Ulcerative; Crohn Disease

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 6, 2026
• First Posted: August 14, 2026
• Study Start: November 6, 2023
• Primary Completion: June 20, 2025
• Study Completion: June 20, 2025
• Last Updated: August 14, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)